LM 22A4
目录号 : GC17835
An agonist of TrkB
Cas No.:37988-18-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | ICR mice are randomly divided into five groups: sham treatment, spinal cord injury, spinal cord injury combined with solvent treatment, spinal cord injury combined with LM22A-4 treatment (10 mg/kg), and spinal cord injury combined with LM22A-4 treatment (15 mg/kg), with each group containing 26 animals. Preparation of the mouse SCI model is based on a previous study and on a protocol employed by this group. Briefly, a mouse is anesthetized via the administration of chloral hydrate (4 mg/kg) before a 3-cm incision is introduced on its back. T7-T11 vertebrae are exposed under a surgical microscope before the laminae are removed with a vascular clip to fully expose the spinal cord. The spinal cord is clamped with the vascular clip for 1 minute with a force of 10 g. The animal is then subjected to complete staunching of the bleeding, and the incised dorsal muscle and skin are sutured. Mice from the control group undergo laminectomy, full exposure of the spinal cord, and subsequent suturing, but without aortic clamping. After the surgery, the mice are placed on a warm blanket until fully awake and are then housed in cages accommodating a normal diet. After the SCI treatment, 14 mice are sacrificed to enable molecular and histological examinations; the other 14 mice are allowed to live for 20 days for neurological scoring and are sacrificed on day 20 via cervical dislocation. |
References: [1]. Yu G, et al. Protective effects of LM22A-4 on injured spinal cord nerves. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6526-32. eCollection 2015. | |
LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.
LM22A-4 significantly up-regulates OPN and ALPase mRNA expression in a dose-dependent manner and OC mRNA level is significantly increased by 5 μM of LM22A-4. LM22A-4 significantly increases OPN, ALPase and OC mRNA expression in a time-dependent manner. LM22A-4 stimulated OPN and OC mRNA expression in HCEM cells cultured with mineralizing media[2].
LM22A-4 (10 mg/kg, i.p.) significantly reduces the degree of tissue injury and apoptosis (TUNEL staining and caspase-3 and Bcl-2 expression) compared with vehicle treated group. LM22A-4 also significantly ameliorates the recovery of limb function. LM22A-4 (10 mg/kg) treatment results in a significant increase in neuron number. LM22A-4 administration (10 mg/kg) significantly improves the neurological scores compared with those of the solvent-treated animals[1].
References:
[1]. Yu G, et al. Protective effects of LM22A-4 on injured spinal cord nerves. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6526-32. eCollection 2015.
[2]. Kajiya M, et al. BDNF mimetic compound LM22A-4 regulates cementoblast differentiation via the TrkB-ERK/Akt signaling cascade. Int Immunopharmacol. 2014 Apr;19(2):245-52.
| Cas No. | 37988-18-4 | SDF | |
| 化学名 | (1Z,3Z,5Z)-N'1,N'3,N'5-tris(2-hydroxyethyl)benzene-1,3,5-tris(carboxylimidic acid) | ||
| Canonical SMILES | OCC/N=C(O)/C1=CC(/C(O)=N/CCO)=CC(/C(O)=N/CCO)=C1 | ||
| 分子式 | C15H21N3O6 | 分子量 | 339.34 |
| 溶解度 | DMF: 10 mg/ml,DMSO: 30 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9469 mL | 14.7345 mL | 29.469 mL |
| 5 mM | 0.5894 mL | 2.9469 mL | 5.8938 mL |
| 10 mM | 0.2947 mL | 1.4734 mL | 2.9469 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。